Treatment of visceral leishmaniasis

Medical Microbiology and Immunology

Volumn 190, Issue 1-2, 2001, Pages 89-92

  Sundar, Shyam ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIHISTAMINIC AGENT; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIPYRETIC AGENT; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; STIBOGLUCONATE SODIUM;

ANTIBIOTIC THERAPY; ARTICLE; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DOSE CALCULATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; INDIA; LEISHMANIASIS; MONOTHERAPY; MYOCARDITIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VISCERAL LEISHMANIASIS;

EID: 0035162724     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004300100088     Document Type: Article

References (28)

1. Human leishmaniasis: Clinical, diagnostic and chemotherapeutic developments in the last 10 years
2. The treatment of kala-azar. New approach to an old problem
3. The leishmaniasis: Report of a WHO Expert Committee
4. The control of leshmaniases: Report of an expert committee
5. Failure of penatavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian Epidemic
6. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases
7. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
8. Kala-azar mortality in hospitalised cases in North Bihar, India
9. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis
10. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani
11. Evaluation of diamidine compounds (pentamidine isethionate) in the treatment of resistant cases of kala-azar occuring in North Bihar, India
12. Comparison of regimens of treatment of antimony-resistant kala-azar patients: A randomized study
13. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonials
14. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies
15. Amphotericin B for second line treatment of Indian kala-azar
16. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B
17. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex
18. Short-course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony
19. Ultra-short-course amphotericin B lipid complex treatment for antimony-unresponsive Indian visceral leishmaniasis
20. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
21. Low dose liposomal amphotericin B in refractory Indian visceral leishmaniasis - A multicenter study
22. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis
23. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate
24. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani
25. Trial of oral miltefosine
26. Oral treatment for visceral leishmaniasis with miltefosine
27. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis
28. Short-course oral miltefosine treatment for visceral leishmaniasis